We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+10.44%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$22M
Cap. Flow
+$60.5M
Cap. Flow %
44.95%
Top 10 Hldgs %
36.29%
Holding
86
New
27
Increased
9
Reduced
17
Closed
23

Top Buys

Rank Stock Value
1
THC icon
Tenet Healthcare
THC
+$4.06M
2
VSTM icon
Verastem
VSTM
+$3.76M
3
PRAX icon
Praxis Precision Medicines
PRAX
+$2.25M
4
APLS
Apellis Pharmaceuticals
APLS
+$1.83M
5
UHS icon
Universal Health Services
UHS
+$1.82M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$3.47M
2
VRDN icon
Viridian Therapeutics
VRDN
+$2.93M
3
SVRA icon
Savara
SVRA
+$2.32M
4
AZN icon
AstraZeneca
AZN
+$2.28M
5
ANAB icon
AnaptysBio
ANAB
+$2.13M

Sector Composition

Rank Sector Weight
1 Healthcare 79.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
26
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
$2.01M 1.5%
+93,222
New +$1.73M
NKTR icon
27
CALL
Nektar Therapeutics
NKTR
$2.39B
$1.94M 1.44%
75,000
+70,000
+1,400% +$786K
WAY
28
Waystar Holding Corp
WAY
$4.54B
$1.92M 1.43%
+46,900
New +$1.81M
CRBP icon
29
Corbus Pharmaceuticals
CRBP
$168M
$1.91M 1.42%
277,317
-12,373
-4% -$89.9K
TXG icon
30
10x Genomics
TXG
$5.97B
$1.9M 1.41%
+163,658
New +$1.49M
DYN icon
31
Dyne Therapeutics
DYN
$4.28B
$1.87M 1.39%
195,933
-62,458
-24% -$688K
RGNX icon
32
Regenxbio
RGNX
$615M
$1.86M 1.38%
226,060
-179,221
-44% -$1.5M
UHS icon
33
Universal Health Services
UHS
$10.1B
$1.83M 1.36%
+10,100
New +$1.82M
VERA icon
34
Vera Therapeutics
VERA
$2.39B
$1.81M 1.34%
+76,700
New +$1.72M
CRNX icon
35
Crinetics Pharmaceuticals
CRNX
$8.88B
$1.8M 1.34%
62,700
+11,405
+22% +$352K
COR icon
36
CALL
Cencora
COR
$62.2B
$1.8M 1.34%
+6,000
New +$1.73M
APLS
37
DELISTED
Apellis Pharmaceuticals
APLS
$1.71M 1.27%
+98,600
New +$1.83M
EWTX icon
38
Edgewise Therapeutics
EWTX
$4.34B
$1.63M 1.21%
124,470
+53,032
+74% +$765K
TVTX icon
39
CALL
Travere Therapeutics
TVTX
$5.2B
$1.63M 1.21%
110,000
– –
BCRX icon
40
BioCryst Pharmaceuticals
BCRX
$2.48B
$1.55M 1.15%
172,883
+112,283
+185% +$1.05M
CLDX icon
41
Celldex Therapeutics
CLDX
$2.79B
$1.49M 1.1%
+73,000
New +$1.42M
RARE icon
42
CALL
Ultragenyx Pharmaceutical
RARE
$2.56B
$1.36M 1.01%
+37,500
New +$1.35M
GOSS icon
43
Gossamer Bio
GOSS
$100M
$1.35M 1%
1,097,999
– –
GPCR icon
44
Structure Therapeutics
GPCR
$3.4B
$1.11M 0.83%
53,744
-49,200
-48% -$1.08M
LEGN icon
45
Legend Biotech
LEGN
$3.68B
$1.03M 0.77%
+29,100
New +$943K
MBX
46
MBX Biosciences
MBX
$2.86B
$720K 0.54%
63,076
-70,037
-53% -$714K
ALVO icon
47
Alvotech
ALVO
$1.05B
$715K 0.53%
78,372
-11,728
-13% -$110K
NAMS icon
48
NewAmsterdam Pharma
NAMS
$3.27B
$662K 0.49%
+36,574
New +$667K
CMPS
49
Compass Pathways
CMPS
$1.46B
$598K 0.44%
+213,544
New +$804K
ESTA icon
50
Establishment Labs
ESTA
$2.7B
$560K 0.42%
13,100
– –
1
2
3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
GIO
Galilei Investment Office London, United Kingdom $193M AUM 16.19% 1-Year Est. Return

Exome Asset Management's Q2 2025 Portfolio in Review

As of Q2 2025, Exome Asset Management held 86 positions worth $135M, up 20% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Exome Asset Management deployed $60.5M of net new capital in Q2 2025, opening 27 new positions and adding to 9 existing holdings. Its largest new stake was Tenet Healthcare: 27,000 shares worth $4.75M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 98% a quarter earlier.

On the sell side, the largest reduction was AnaptysBio, an estimated $2.13M trimmed.

  • Exome Asset Management's largest Q2 2025 buy was Tenet Healthcare: 27,000 shares worth $4.75M.
  • Exome Asset Management added most to BioCryst Pharmaceuticals in Q2 2025, an estimated $1.05M increase.
  • Exome Asset Management's biggest Q2 2025 reduction was AnaptysBio, cutting an estimated $2.13M.
  • Exome Asset Management fully exited Akero Therapeutics in Q2 2025, selling an estimated $3.47M.
  • Exome Asset Management's ten largest holdings make up 36% of its $135M portfolio in Q2 2025.
  • Exome Asset Management opened 27 new positions and closed 23 in Q2 2025.
  • Exome Asset Management's portfolio value rose 20% quarter-over-quarter to $135M.

Based on Exome Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.